Cancer immunotherapy and targeted therapy advances
Key Questions
What is the significance of the first CAR-T approval for solid tumors?
China approved the first CAR-T therapy for gastric cancer, a solid tumor. This marks a historic expansion beyond hematologic malignancies.
What survival benefits were seen with daraxonrasib in pancreatic cancer?
Daraxonrasib nearly doubled survival times. The combination with vopimetostat achieved a 92% response rate and received EMA expedited review.
How effective was allogeneic CAR-T in solid tumors like renal cell carcinoma?
ALLO-316 produced the first durable remissions in solid tumors with a 31% response rate in RCC. This demonstrates feasibility of off-the-shelf CAR-T approaches.
What long-term data supports CAR-T in B-cell lymphoma?
CAR-T therapies have shown 10-year remissions in B-cell lymphoma patients. Outpatient monitoring has also proven safe in recent studies.
Which immunotherapy combination showed durable survival in colorectal cancer?
Nivolumab plus ipilimumab provided 3-year survival in dMMR/MSI-H metastatic colorectal cancer. Pembrolizumab monotherapy outperformed chemotherapy in dMMR endometrial cancer per KEYNOTE-C93.
What CAR-T results were reported for pediatric brain tumors and glioblastoma?
Multi-target CAR-T (WT1, PRAME, Survivin) produced durable responses in pediatric brain tumors. Spinal fluid delivery led to complete tumor disappearance in some glioblastoma cases.
What new FDA approvals occurred for multiple myeloma and bladder cancer therapies?
Subcutaneous isatuximab was approved for multiple myeloma. KEYTRUDA plus Padcev received approval for muscle-invasive bladder cancer.
How are new engineering strategies improving CAR-T performance?
AstraZeneca's dnTGFeta RII armoring and trispecific CAR-T designs (CD19/20/22) showed high complete response rates. MAPK/ERK signaling was identified as a predictive biomarker for glioblastoma immunotherapy response.
First CAR-T approval for solid tumor (gastric cancer) in China. Daraxonrasib nearly doubles pancreatic cancer survival; vopimetostat-daraxonrasib combo 92% response; EMA expedited review. KEYNOTE-942 5-year data (49% recurrence reduction). CAR-T for glioblastoma via spinal fluid leads to complete tumor disappearance. CAR-T 10-year remissions in B-cell lymphoma. ASCO 2026: mezigdomide + carfilzomib reduces risk by 52% in RRMM; teclistamab HR 0.29; KLN-1010 in vivo CAR T 100% ORR. IDH1 peptide vaccine 66% survival at 8 years in gliomas. Gut bacteria molecule doubles lung cancer immunotherapy response. KEYNOTE-C93 shows pembrolizumab monotherapy beats platinum-doublet in dMMR endometrial cancer. Nivolumab+ipilimumab provides durable 3-year survival in dMMR/MSI-H metastatic colorectal cancer. Multi-target CAR-T (WT1, PRAME, Survivin) for pediatric brain tumors shows durable responses. Allogeneic CAR T (ALLO-316) achieves first durable remissions in solid tumors (RCC, 31% response). CAR-T for T-ALL (CD7-targeted) FDA breakthrough designation with 73% remission. GPNMB-targeted CAR T shows promise. FDA approved subcutaneous isatuximab for multiple myeloma. FDA approved KEYTRUDA + Padcev for MIBC. MAGE-A4 TCR therapy full FDA approval. First T-reg therapy in BMT approved. Outpatient CAR-T monitoring safe. Risvutatug rezetecan (B7-H3 ADC) positive Phase III OS in relapsed SCLC. CAR T in AL amyloidosis shows rapid organ recovery. Confluence Genetics Cas-CLEAR selectively shreds chromatin in p53-mutant cancer cells. Europe approved epcoritamab-R² for early relapsed follicular lymphoma. Preclinical intravesical CAR-T targeting MUC16 for bladder cancer. CAR-T cells reshape tumor microenvironment bidirectionally. Gedatolisib (PI3K inhibitor) pending FDA decision July 17 for PIK3CA wild-type breast cancer; Phase 3 data shows 76% risk reduction. Qihan's QT-019B allogeneic CAR-T (CD19/BCMA) receives RMAT, BTD, Fast Track designations. irAE management guidance published; MAPK/ERK signaling identified as predictive biomarker for GBM immunotherapy response; NSCLC multi-omics study identifies LRP1B/FBXW7 mutations as predictors for ICI+chemo response. AstraZeneca's dnTGFβRII armoring strategy for CAR T cells shows promise. GCC-targeting CAR-T for colorectal cancer shows encouraging activity. LAG-3 discovery story highlights translation from gene discovery to approved melanoma combo therapy. New: Yan Leyfman presented trispecific CAR T (CD19/20/22) with 83% CR in lymphoma, 7-day vein-to-vein time; baseline T-cell exhaustion predicts progression.